Resumo

ARANGO-GIL, Isaac Santiago; MARTINEZ, Alonso; CHICA, Julián Echeverry  e  PEREZ-CALA, Tania Liseth. Rifabutin: therapeutic alternative for Helicobacter pylori infection, actual literature review. Medicas UIS [online]. 2022, vol.35, n.1, pp.31-42.  Epub 28-Maio-2022. ISSN 0121-0319.  https://doi.org/10.18273/revmed.v35n1-2022003.

Helicobacter pylori infection is associated with gastroduodenal diseases such as chronic gastritis, peptic ulcer, and gastric adenocarcinoma. Nowadays, there are different therapeutic regimens, however, the indiscriminate use of antibiotics generated resistance in this agent, reason to study alternatives and reevaluate the criteria that determines the selection of a specific regimen. The aim of this review was to describe the general principles of treatment according to reference guidelines and recommendations of independent authors, and to present the use of rifabutin as a therapeutic alternative. The bibliographic search was performed using the terms “Helicobacter pylori” AND “rifabutin” in the databases PubMed, SciELO and the search engine Google Scholar®. Current evidence suggests that the use of rifabutin as rescue therapy is appropriate and safe, and would be an ideal alternative in cases of multidrug resistance or difficult access to antibiotic susceptibility tests. MÉD.UIS.2022;35(1): 31-42.

Palavras-chave : Helicobacter pylori; Rifabutin; Gastritis; Peptic ulcer; Stomach neoplasms.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )